NuGen Medical Devices Inc.
NGMD.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -78.26% | -79.66% | -93.54% | 46.79% | 131.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -78.26% | -79.66% | -93.54% | 46.79% | 131.25% |
| Cost of Revenue | -78.57% | -73.22% | -95.06% | 52.38% | 133.33% |
| Gross Profit | -77.78% | -85.13% | -92.02% | 43.28% | 130.77% |
| SG&A Expenses | 44.88% | 10.26% | -46.23% | 59.54% | -47.56% |
| Depreciation & Amortization | 9.02% | 26.99% | -- | 1.37% | -14.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.21% | -0.07% | -54.32% | 45.93% | -41.30% |
| Operating Income | -47.60% | -38.06% | 44.53% | -45.91% | 46.83% |
| Income Before Tax | -206.82% | -1,121.18% | 37.15% | -141.63% | 180.73% |
| Income Tax Expenses | -- | 1,342.86% | -141.77% | -- | -- |
| Earnings from Continuing Operations | -207.09% | -1,122.88% | 37.52% | -142.06% | 180.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -207.09% | -1,122.88% | 37.52% | -142.06% | 180.53% |
| EBIT | -47.60% | -38.06% | 44.53% | -45.91% | 46.83% |
| EBITDA | -56.49% | -44.44% | 48.67% | -59.83% | 51.84% |
| EPS Basic | -206.25% | -1,064.71% | 40.00% | -131.25% | 172.73% |
| Normalized Basic EPS | -206.67% | -291.30% | 40.32% | -119.05% | 173.17% |
| EPS Diluted | -206.25% | -1,064.71% | 40.00% | -131.25% | 172.73% |
| Normalized Diluted EPS | -206.67% | -291.30% | 40.32% | -119.05% | 173.17% |
| Average Basic Shares Outstanding | 0.25% | 3.45% | 4.47% | 5.17% | 10.48% |
| Average Diluted Shares Outstanding | 0.25% | 3.45% | 4.47% | 5.17% | 10.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |